MULTIPLE DRUG RESISTANCE: TRENDS AND IMPLICATIONS

Authors: Cray, Paula; HEADRICK, MARCIA - FDA-CVM; Englen, Mark; Gray, Jeffrey; Jackson, Charlene; Tankson, Jeanetta; ANANDARAMAN, NEENA - USDA-FSIS; SALAMONE, BEN - USDA-FSIS; ROSE, BONNIE - USDA-FSIS; DARGATZ, DAVE - USDA-APHIS

Submitted to: International Association for Food Protection
Publication Type: Abstract Only
Publication Acceptance Date: 3/3/2002
Publication Date: 4/3/2002
Citation: Cray, P.J., Headrick, M., Englen, M.D., Gray, J.T., Jackson, C.R., Tankson, J.D., Anandaraman, N., Salamone, B., Rose, B., Dargatz, D.A. 2002. Multiple drug resistance: trends and implications. International Association for Food Protection. 749-750.

Interpretive Summary:

Technical Abstract: Antimicrobial resistance (AR) has emerged as a global problem. Although AR occurs shortly after the introduction and use of an antimicrobial, resistance levels vary over time. Historically, antimicrobials were regarded as wonder drugs and for years, when resistance to a single antimicrobial occurred, resistance was overcome by the use of newer, more effective antimicrobials. However, drug development has slowed and multiple AR (MAR) has developed. The development of MAR has become a serious concern in the animal and human health communities as MAR compromises treatment and impacts outcome, potentially leading to increased morbidity and mortality. The National Antimicrobial Resistance Monitoring System (NARMS) tracks the emergence of AR in Salmonella, Campylobacter, E.coli, and enterococci. Since the inception of NARMS in 1996, more than 30,000 isolates originating from animals or the production environment have been tested for AR, and MAR analysis was conducted. MAR has emerged in foodborne and commensal bacteria. Many factors, including (but not limited to) serotype, species, resistance to compounds other than antimicrobials, and movement of mobile genetic elements, influence the development of MAR.